Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386988439> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4386988439 endingPage "683" @default.
- W4386988439 startingPage "675" @default.
- W4386988439 abstract "L’asthme sévère reste relativement rare chez l’enfant. L’asthme sévère n’est plus considéré comme une maladie unique mais plutôt comme un syndrome correspondant à différents phénotypes et voies physiopathologiques. Les biomarqueurs utilisables pour le phénotypage comprennent essentiellement le dosage d’IgE spécifiques, les éosinophiles sanguins, la fraction exhalée du NO (FeNO) et certains biomarqueurs du poumon profond issues des expectorations induites, du lavage bronchoalvéolaire ou de la biopsie bronchique. Chez l’enfant, les biothérapies actuellement approuvées dans l’asthme sévère, dès l’âge de 6 ans, sont l’omalizumab, le mépolizumab et le dupilumab, et le tezepelumab dès l’âge de 12 ans. Le benralizumab et le tezepelumab offrent des perspectives intéressantes et une extension pédiatrique de leur utilisation pourrait offrir de nouvelles alternatives dans l’asthme sévère de l’enfant. Les biothérapies représentent une approche nouvelle et prometteuse dans le traitement de l’asthme, basé sur des mécanismes physiopathologiques. L’efficacité prolongée et l’impact de ces traitements sur l’histoire naturelle de la maladie doivent être étudiés plus avant. Il est crucial de prendre en compte les spécificités de l’asthme pédiatrique et de notamment mener des essais cliniques chez les patients plus jeunes. Severe asthma in children remains relatively rare. It is no longer considered as a single disease but rather as a syndrome corresponding to different phenotypes and distinct pathophysiological pathways. Various biomarkers can contribute to phenotyping, essentially specific IgE test results, blood eosinophil counts, the exhaled fraction of NO (FeNO) assay, as well as deep lung biomarkers from induced sputum, bronchoalveolar lavage or bronchial biopsy. In children, the biologics currently approved for severe asthma are omalizumab, mepolizumab and dupilumab from the age of 6, and tezepelumab from the age of 12. Benralizumab and tezepelumab offer promising perspectives and a pediatric extension could be of interest in future treatment of severe pediatric asthma. Based on physiopathological mechanisms, biologics represent a new and promising approach in the treatment of asthma. That said, the long-term efficacy and impact of these treatments on the natural history of the disease require further investigation. It is of paramount importance to take into account the specificities of pediatric asthma and, more particularly, to conduct clinical trials in younger patients." @default.
- W4386988439 created "2023-09-24" @default.
- W4386988439 creator A5043312990 @default.
- W4386988439 date "2023-10-01" @default.
- W4386988439 modified "2023-10-13" @default.
- W4386988439 title "Les biothérapies en 2023 dans l’asthme sévère de l’enfant" @default.
- W4386988439 cites W1876031798 @default.
- W4386988439 cites W1898930241 @default.
- W4386988439 cites W1928142138 @default.
- W4386988439 cites W1966079364 @default.
- W4386988439 cites W1971242419 @default.
- W4386988439 cites W1983832849 @default.
- W4386988439 cites W1988223366 @default.
- W4386988439 cites W2010946738 @default.
- W4386988439 cites W2020989669 @default.
- W4386988439 cites W2024286006 @default.
- W4386988439 cites W2037420723 @default.
- W4386988439 cites W2041651163 @default.
- W4386988439 cites W2066531673 @default.
- W4386988439 cites W2075699130 @default.
- W4386988439 cites W2098691482 @default.
- W4386988439 cites W2101548824 @default.
- W4386988439 cites W2114436422 @default.
- W4386988439 cites W2136710755 @default.
- W4386988439 cites W2138355864 @default.
- W4386988439 cites W2146852572 @default.
- W4386988439 cites W2160953471 @default.
- W4386988439 cites W2164548578 @default.
- W4386988439 cites W2511120040 @default.
- W4386988439 cites W2513258422 @default.
- W4386988439 cites W2528058588 @default.
- W4386988439 cites W2604291894 @default.
- W4386988439 cites W2610654869 @default.
- W4386988439 cites W2619633721 @default.
- W4386988439 cites W2761487814 @default.
- W4386988439 cites W2761520475 @default.
- W4386988439 cites W2791719145 @default.
- W4386988439 cites W2803625106 @default.
- W4386988439 cites W2803941918 @default.
- W4386988439 cites W2805002966 @default.
- W4386988439 cites W2810762000 @default.
- W4386988439 cites W2902099490 @default.
- W4386988439 cites W2915525302 @default.
- W4386988439 cites W3029612125 @default.
- W4386988439 cites W3030200031 @default.
- W4386988439 cites W3093888464 @default.
- W4386988439 cites W3113273155 @default.
- W4386988439 cites W3117504892 @default.
- W4386988439 cites W3127475118 @default.
- W4386988439 cites W3162024685 @default.
- W4386988439 cites W3176401948 @default.
- W4386988439 cites W4200366508 @default.
- W4386988439 cites W4281655110 @default.
- W4386988439 cites W4290999808 @default.
- W4386988439 cites W4312056500 @default.
- W4386988439 doi "https://doi.org/10.1016/j.rmr.2023.09.002" @default.
- W4386988439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37749027" @default.
- W4386988439 hasPublicationYear "2023" @default.
- W4386988439 type Work @default.
- W4386988439 citedByCount "0" @default.
- W4386988439 crossrefType "journal-article" @default.
- W4386988439 hasAuthorship W4386988439A5043312990 @default.
- W4386988439 hasConcept C126322002 @default.
- W4386988439 hasConcept C2777714996 @default.
- W4386988439 hasConcept C29456083 @default.
- W4386988439 hasConcept C2983914783 @default.
- W4386988439 hasConcept C71924100 @default.
- W4386988439 hasConceptScore W4386988439C126322002 @default.
- W4386988439 hasConceptScore W4386988439C2777714996 @default.
- W4386988439 hasConceptScore W4386988439C29456083 @default.
- W4386988439 hasConceptScore W4386988439C2983914783 @default.
- W4386988439 hasConceptScore W4386988439C71924100 @default.
- W4386988439 hasIssue "8" @default.
- W4386988439 hasLocation W43869884391 @default.
- W4386988439 hasLocation W43869884392 @default.
- W4386988439 hasOpenAccess W4386988439 @default.
- W4386988439 hasPrimaryLocation W43869884391 @default.
- W4386988439 hasRelatedWork W1506200166 @default.
- W4386988439 hasRelatedWork W1995515455 @default.
- W4386988439 hasRelatedWork W2048182022 @default.
- W4386988439 hasRelatedWork W2080531066 @default.
- W4386988439 hasRelatedWork W2604872355 @default.
- W4386988439 hasRelatedWork W2748952813 @default.
- W4386988439 hasRelatedWork W2899084033 @default.
- W4386988439 hasRelatedWork W3031052312 @default.
- W4386988439 hasRelatedWork W3032375762 @default.
- W4386988439 hasRelatedWork W3108674512 @default.
- W4386988439 hasVolume "40" @default.
- W4386988439 isParatext "false" @default.
- W4386988439 isRetracted "false" @default.
- W4386988439 workType "article" @default.